If You Invested in Pasithea Therapeutics Corp (KTTA)
Custom Calculation
Choose your own date and amount for KTTA$1,000 Investment Over Time
KTTA vs S&P 500Year-by-Year Returns
KTTA annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2021 | $71.20 | $35.40 | -50.3% | -50.3% |
| 2022 | $35.80 | $12.83 | -64.2% | -82.0% |
| 2023 | $12.85 | $7.40 | -42.4% | -89.6% |
| 2024 | $8.05 | $3.15 | -60.9% | -95.6% |
| 2025 | $2.93 | $1.29 | -56.0% | -98.2% |
| 2026 | $1.19 | $0.78 | -34.4% | -98.9% |
About Pasithea Therapeutics Corp
Pharmaceutical Preparations · NASDAQ
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company developing drug candidates for central nervous system disorders, RASopathies, MAPK pathway-driven tumors and other diseases. The company’s common stock trades on The Nasdaq Capital Market under the symbol KTTA, and its listed warrants trade under KTTAW. Pasithea is organized as a Delaware corporation and reports its principal executive office in Miami Beach, Florida.
The company’s current development focus is PAS-004, a next-generation macrocyclic MEK inhibitor. MEK inhibition targets signaling in the MAPK pathway, a biology area relevant to RASopathies and certain tumors. Pasithea describes PAS-004 as its lead therapeutic candidate and has positioned the program for neurofibromatosis type 1, including NF1-associated plexiform neurofibromas and cutaneous neurofibromas, as well as MAPK pathway-driven tumors and other diseases.
Lead program and disease focus
Pasithea’s PAS-004 program is centered on diseases where aberrant MAPK pathway signaling is a therapeutic target. The company has identified neurofibromatosis type 1, or NF1, as a principal indication area, with clinical development directed at NF1-associated plexiform neurofibromas and related manifestations. The company has also reported clinical development activity in advanced cancer and research activity related to amyotrophic lateral sclerosis, or ALS.
PAS-004 has received U.S. Food and Drug Administration regulatory designations for specific NF1 uses, including Orphan Drug Designation, Fast Track Designation and Rare Pediatric Disease Designation. These designations are part of the regulatory framework for developing therapies for serious, rare or pediatric diseases and are distinct from product approval. Pasithea remains a development-stage company, and its business model depends on research, clinical development, regulatory progress, financing activity and potential future commercialization or licensing outcomes.
Business model and operating structure
Pasithea operates as a biotechnology research and development company rather than as a commercial drug seller. Its recurring activities include preclinical research, clinical trial execution, regulatory communications, medical strategy, intellectual property development, financing transactions and corporate governance. The company’s reported business is focused on research and development of treatments for central nervous system disorders and other diseases, including RASopathies and certain cancers.
Like many clinical-stage biotechnology issuers, Pasithea funds its operations through capital markets activity and other financing sources while advancing its product candidates through clinical and regulatory pathways. Company disclosures also reference potential use of capital for ongoing research, clinical trials, development of biological and pharmaceutical technologies, licensing activities, acquisitions of complementary technologies or businesses and working capital.
Public-company profile
Pasithea is an emerging growth company under U.S. securities rules, according to its SEC filings. Its public-company disclosures cover its common stock and warrants, registration statements for securities offerings, governance matters, equity incentive plan approvals, executive appointments, Regulation FD communications, Nasdaq listing compliance matters, and risk factors associated with a clinical-stage biotechnology company. These disclosures frame Pasithea as a focused drug-development issuer whose value proposition is tied primarily to PAS-004 and related clinical, regulatory and financing developments.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Pasithea Therapeutics Corp investment returns
How much would $1,000 invested in Pasithea Therapeutics Corp be worth today?
If you invested $1,000 in Pasithea Therapeutics Corp (KTTA) 10 years ago on 2021-09-15, your investment would be worth $11 today, representing a -98.9% total return, growing at a compounded rate of -62.0% per year (CAGR).
Has Pasithea Therapeutics Corp outperformed the S&P 500?
Over the past 10 years, KTTA returned -98.9% compared to +260.7% for the S&P 500, underperforming the benchmark by 359.6 percentage points.
What is Pasithea Therapeutics Corp's average annual return?
The compound annual growth rate (CAGR) of KTTA over the past 10 years is -62.0%, growing at a compounded rate each year. Individual years vary significantly — KTTA's best recent year was 2026 (-34.4%) and worst was 2022 (-64.2%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
